Metabolic · Research reference

Retatrutide 20mg

Triple-agonist — single vial. Next-generation triple-receptor agonist (GLP-1 + GIP + glucagon). 20mg per vial for metabolic pathway research.

See the wiki entry

Half-life

~6 days (SC)

Molar mass

4731.4 g/mol

Purity floor

≥99%

CAS

2381089-83-2

Mechanism

Retatrutide is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. In vitro it activates all three receptors with sub-nanomolar potency in cAMP-accumulation assays, with characterized bias profiles distinct from dual-agonist Tirzepatide.

Common in-vitro applications

GLP-1/GIP/glucagon receptor signaling
cAMP accumulation + β-arrestin recruitment assays in CHO cells stably expressing each receptor.
Working range: pM to nM range
Adipocyte lipolysis modeling
Comparative lipolysis assays in 3T3-L1 differentiated adipocytes vs Tirzepatide.
Working range: 1 nM to 100 nM
Hepatic energy expenditure
Mitochondrial respiration (Seahorse XF) measurements in HepG2 hepatocytes.
Working range: 10 nM to 1 µM

Reconstitution + storage

Reconstitution

3ml bacteriostatic water → 6.6mg/ml

Per-vial mass

20mg

Lyophilized storage

−20°C or below, desiccated

Reconstituted storage

2–8°C, use within 30 days

Light + air

Protect from light and air

Solubility

Soluble in bacteriostatic water (0.9% benzyl alcohol)

Background: lyophilization · reconstitution

Co-treatment partners

Tirzepatide
Side-by-side dual vs triple agonist comparison in receptor activation panels.
Semaglutide
Single-agonist baseline for receptor-bias and ligand-residency studies.

Selected peer-reviewed citations

Coskun T, et al. (2022). LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist. Cell Metabolism.
Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine.

Verification

Read the COA

Open the batch lookup — Janoshik HPLC-UV + ESI-MS packet.

Open

Buy this kit

Retatrutide 20mg · $175

Lyophilized, COA-verified, tracked US shipping.

Open the PDP

Reference data is supplied for in-vitro literature context only. Aurex does not provide dosage or use guidance — Federal regulations governing research-chemical distribution prohibit it. Retatrutide 20mg is sold for in-vitro research applications only, by qualified researchers. Not for human or veterinary use. Not FDA approved.